Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
741 to 760 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ribosomal Incorporation of Lithocholic Acid into Peptides for the De Novo Discovery Of Peptide-Lithocholic Acid Hybrid Macrocyclic Peptides. | ACS Chem Biol | 2024 | 38901034 | PubTator, text mining | PubMed |
| Trophoblast cell surface antigen-2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma. | BJU Int | 2024 | 38897814 | PubTator, text mining | PubMed |
| Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer. | Cancer Med | 2024 | 38895886 | PubTator, text mining | PubMed |
| Identification and Characterization of Metastasis-Initiating Cells in ESCC in a Multi-Timepoint Pulmonary Metastasis Mouse Model. | Adv Sci (Weinh) | 2024 | 38864342 | PubTator, text mining | PubMed |
| Sopa: a technology-invariant pipeline for analyses of image-based spatial omics. | Nat Commun | 2024 | 38862483 | PubTator, text mining | PubMed |
| [Efficacy of sacituzumab govitecan in a patient with TNBC with early relapse after neoadjuvant chemotherapy.] | Recenti Prog Med | 2024 | 38853739 | PubTator, text mining | PubMed |
| Antibody drug conjugate, a level-up version of monoclonal antibody? | Int J Surg | 2024 | 38833359 | PubTator, text mining | PubMed |
| Expanding the horizons of targeted protein degradation: A non-small molecule perspective. | Acta Pharm Sin B | 2024 | 38828146 | PubTator, text mining | PubMed |
| Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer. | J Cancer | 2024 | 38817863 | PubTator, text mining | PubMed |
| TROP2 promotes the proliferation of triple-negative breast cancer cells via calcium ion-dependent ER stress signaling pathway. | Cell Biochem Biophys | 2024 | 38816653 | PubTator, text mining | PubMed |
| A novel fatty acid metabolism-related signature identifies MUC4 as a novel therapy target for esophageal squamous cell carcinoma. | Sci Rep | 2024 | 38816411 | PubTator, text mining | PubMed |
| Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development. | Pharmaceutics | 2024 | 38794336 | PubTator, text mining | PubMed |
| Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs. | Pharmaceuticals (Basel) | 2024 | 38794221 | PubTator, text mining | PubMed |
| Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors. | Diagnostics (Basel) | 2024 | 38786342 | PubTator, text mining | PubMed |
| Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer. | Ther Adv Urol | 2024 | 38779496 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. | BioDrugs | 2024 | 38767823 | PubTator, text mining | PubMed |
| Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. | NPJ Precis Oncol | 2024 | 38760413 | PubTator, text mining | PubMed |
| Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer. | Cancers (Basel) | 2024 | 38730739 | PubTator, text mining | PubMed |
| Trop-2 expression and the tumor immune microenvironment in cervical cancer. | Gynecol Oncol | 2024 | 38723340 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. | Clin Cancer Res | 2024 | 38709212 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=38